Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 4.7% – What’s Next?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA)’s stock price dropped 4.7% during mid-day trading on Thursday . The stock traded as low as $0.2695 and last traded at $0.2979. 1,613,029 shares were traded during trading, a decline of 73% from the average session volume of 5,891,854 shares. The stock had previously closed at $0.3127.

Kairos Pharma Price Performance

The business has a 50 day simple moving average of $0.42 and a 200 day simple moving average of $0.56. The stock has a market cap of $6.10 million, a PE ratio of -0.95 and a beta of 1.50.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter. As a group, sell-side analysts forecast that Kairos Pharma, Ltd. will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kairos Pharma

An institutional investor recently raised its position in Kairos Pharma stock. XTX Topco Ltd raised its holdings in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) by 290.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,494 shares of the company’s stock after acquiring an additional 36,086 shares during the quarter. XTX Topco Ltd owned about 0.23% of Kairos Pharma worth $34,000 at the end of the most recent quarter.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.